Introduction
============

Intracranial aneurysms (IAs) affect approximately 2% of the general population and account for 85% of subarachnoid hemorrhage (SAH) ([@B1], [@B2]). IA rupture is common at the age of 40--60 yr and the prognosis after rupture is poor: about fifty percent of the cases die and another twenty percent cases remain disability after treatment and rehabilitation ([@B3]--[@B5]).

Various theories have been proposed for the development of IA, and IA is always considered as a multifactorial disorder due to the interaction of both environmental and genetic factors. Environmental factors, such as alcohol consumption, smoking, and hypertension seem to be common IA risk factors ([@B6], [@B7]). However, the genetic factors cannot be excluded for the risk of IAs. A familial predisposition was the strongest risk factor for the development of IA, with the risk of rupture increased to 7-fold ([@B8]). Another research also reported a four-fold risk of aneurismal rupture in a first degree relative among the familial clustering of IAs ([@B9]). Similar conclusion was detected in studies of twins. Moreover, the gene factors that result in the changes of vascular extracellular matrix (ECM) may also be an important reason for IAs susceptibility. ECM remodeling plays an important role in maintaining the structure and integrity of the arterial wall. Reduced extracellular matrix is a prominent feature of cerebral aneurysms.

Previous papers have explored a list of genes involved in the maintenance of the integrity of the ECM with case-control studies ([@B10], [@B11]). Among which, the heparan sulfate proteoglycan 2 (*HSPG2*) and chondroitin sulfate proteoglycan 2 (*CSPG2*) genes have been identified as susceptibility genes for IA ([@B12], [@B13]). However, the association between the SNPs of *CSPG2* and *HSPG2* and risk of IAs remains argumentative due to the contrary of the reported researches. The importance of SNPs of *CSPG2* and *HSPG2* in the etiology of IA would be strengthened if the associations could be confirmed in large and various populations. The present study aimed to detect the relationships between various SNPs of *CSPG2* and *HSPG2* and risk of IAs susceptibility via meta-analysis and system review.

Methods
=======

The Cochrane Library, Medline, PubMed, and Embase databases were carefully searched independently by L.H.H and H.W to detect relevant studies published before Mar 30, 2018. The search criteria "VCAN or chondroitin sulfate proteoglycan 2 or *CSPG2* or proteoglycans perlecan or heparan sulfate proteoglycan 2 or *HSPG2*" and "intracranial aneurysm" were used for text word searches. The "related articles" function was used for potentially additional articles. The reference lists of the selected articles were also manually examined to find relevant studies that were not discovered during the above-mentioned database searches. The language was restricted to only English.

All published case-control studies reporting genetic polymorphisms of "*CSPG2* or *HSPG2*" in IAs was potentially enrolled in the present research. All the papers were assessed carefully for eligibility with the titles, abstracts and finally full papers. When several papers from the same study were published, only the most recent or informative one was included.

Data extraction:

The data extraction of all outcomes and variables of interest were performed independently by L.H.H and H.W. Disagreements were resolved through discussion and consensus. Data on author affiliation, number of participants, patients' data and genotyping information were extracted. If insufficient data were reported, we contacted corresponding authors for additional information and the paper was excluded if there was no response.

Quality assessment
------------------

The quality assessment of the included studies was performed independently by the two reviewers L.H.H and H.W using the Newcastle-Ottawa Scale (NOS). The NOS employed a star rating system to assess quality from 3 broad perspectives of the study: 1) selection of the study groups, 2) comparability of the groups, and 3) identification of the exposure (for case-control studies) or outcome of interest (for cohort studies). Scores ranged from 0 to 9 stars, and studies with no less than 7 stars were considered to be of high quality.

Statistical analysis
--------------------

The statistical analysis was performed with the software named ''Comprehensive Meta-Analysis (Version 2.2, Englewood, USA)''. The association strength between the gene polymorphisms and IAs susceptibility was calculated by the Z test, presented with the OR (respective 95% CIs). And the significance of the pooled OR was determined with *P*-values (less than 0.05 was considered significant). I^2^ statistics, with the value ranged from 0% to 100% (complete consistency to complete inconsistency), was used to determine the statistical heterogeneity among studies. If the I^2^ -value was more than 50%, the random-effects model was chosen to calculate the pooled OR; otherwise the fixed-effects model was used. All of the results were presented as forest plots.

Results
=======

The initial literature search retrieved 87 relevant articles (duplicates were discarded), and finally, 7 studies were included in the present study after carefully review. Flowcharts describing the study selection was shown in [Fig. 1](#F1){ref-type="fig"}.

![Search strategy flow diagram](IJPH-48-1945-g001){#F1}

Overall, 8651 participations (3674 with IAs and 4977 for control) were enrolled in the studs. All the patients were radiologically confirmed intracranial aneurismal cases and the controls were age and gender matched. [Table 1](#T1){ref-type="table"} listed the basic information of the included studies. Only 4 SNPs of the two genes (rs173686, rs251124, rs3767137, and rs7556412) were matched across at least three studies and were finally included in the study. The review of the information and data extraction revealed 100% agreement between the 2 reviewers.

###### 

Characteristics of the individual studies included in the meta-analysis

  ***Pmid***   ***Country***   ***Year***   ***Author***      ***Inclusion***                                                    ***Number***   ***Matched snps***   
  ------------ --------------- ------------ ----------------- -------------------------------------------------------- --------- -------------- -------------------- --------------------------------
  25606449     India           2014         Moinak banerjee   Radiologically confirmed intracranial aneurismal cases             220            250                  Rs251124, rs173686
  23568740     China           2013         Lijuan hu         Radiologically confirmed intracranial aneurismal cases             537            1071                 Rs251124, rs3767137
  20053631     Netherlands     2010         Ynte m. Ruigrok   Radiologically confirmed intracranial aneurismal cases   Stage 1   376            648                  Rs173686, rs3767137, rs7556412
  Stage 2      360             376                                                                                                                                   
  19506372     Japan           2009         Boris krischek    Radiologically confirmed intracranial aneurismal cases             632            808                  Rs251124, rs3767137
  18484070     China           2007         Jizong zhao       Radiologically confirmed intracranial aneurismal cases             240            240                  Rs251124, rs173686
  17038484     Netherlands     2006         Ynte m. Ruigrok   Radiologically confirmed intracranial aneurismal cases   Stage 1   382            609                  Rs3767137, rs7556412
  Stage 2      310             336                                                                                                                                   
  16917090     Netherlands     2006         Ynte m. Ruigrok   Radiologically confirmed intracranial aneurismal cases   Stage 1   307            639                  Rs251124, rs173686
  Stage 2      310                                                                                                                                                   

Main analysis
-------------

The genotype and allele frequencies of the *CSPG2* and *HSPG2* gene variants between patients and controls were extracted and analyzed from the included studies. Only the meta-analysis of the allele frequencies was able to conduct between the studies, the meta-analysis of the genotype frequencies was not available because of the limited data. The meta-analysis for the relationship between gene *CSPG2* (rs173686, rs251124) or *HSPG2* (rs173686, rs251124) polymorphisms and IAs susceptibility were shown in [Table 2](#T2){ref-type="table"}.

###### 

Meta-analysis of associations between *CSPG2* and *HSPG2* polymorphisms and IAs susceptibility

  ***Gene***   ***SNP***   ***Number***   ***Effect model***   ***A vs. A***                           
  ------------ ----------- -------------- -------------------- --------------- ----------------------- -------
  *CSPG2*      Rs173686    1442           1778                 Random          1.110 (0.926-- 1.332)   0.259
  *CSPG2*      Rs251124    2227           2845                 Random          1.129 (1.029-- 1.238)   0.01
  *HSPG2*      Rs3767137   1700           2401                 Fixed           0.842 (0.759-- 0.935)   0.001
  *HSPG2*      Rs7556412   1068           1593                 Random          1.063 (0.899-- 1.258)   0.474

For the rs251124 polymorphism of *CSPG2*, the quantitative synthesis from 5 studies showed the gene allele significant difference in the gene allele comparison of T vs. C (OR, 1.129; 95% CI, 1.029, 1.238; *P*=0.01) ([Fig. 2](#F2){ref-type="fig"}). However, for the rs173686 polymorphism of *CSPG2*, no significant difference was found in the gene allele comparison (*P=*0.259).

![The forest plots present the association between polymorphism of rs251124 and IAs susceptibility. Number of included studies: n*=*5; OR, 1.129; 95% CI, 1.029, 1.238; *P=*0.01)](IJPH-48-1945-g002){#F2}

Similarly, for SNPs rs3767137 of *HSPG2*, quantitative synthesis showed significant differences in the comparisons of allele frequencies (A vs. G, OR, 0.842, 95% CI*=*0.759--0.935, *P=*0.001, [Fig. 3](#F3){ref-type="fig"}). And no significant difference was found in the gene allele comparison for the rs7556412 polymorphism of *HSPG2* (*P=* 0.474).

![The forest plots present the association between polymorphism of rs3767137 and IAs susceptibility. Number of included studies: n=4; OR, 0.842, 95% CI*=*0.759--0.935, *P=*0.001)](IJPH-48-1945-g003){#F3}

Publication bias
----------------

Egger\'s test was performed to access the publication bias of studies included in this meta-analysis. The Egger\'s test demonstrated no evidence of publication bias for all the four SNPs.

Discussion
==========

The study demonstrated the SNPs rs251124 of *CSPG2* and rs3767137 of *HSPG2* had statistically significant associations with IAs susceptibility. The minor allele T of rs251124 demonstrated a harmful effect but the minor allele A of rs3767137 demonstrated a protective role with regard to the risk of IAs. However, no such associations were found in the SNPs rs173686 of *CSPG2* and rs7556412 of *HSPG2*. Because of the increasing number of cases and controls in this analysis, the estimates of association obtained are more precise.

The pathology of IA is the ballooning of intracranial arteries that is easy to rupture or constrict the nerves. IAs is caused by weakening of arterial walls, which indicates the role of defective ECM in IA pathogenesis. Gene *CSPG2* and *HSPG2* encode two important proteins in maintains of the ECM, thus the genotype variations of *CSPG2* and *HSPG2* and the resulting functional changes may be an important part of IAs pathologies. Until now, contrary results were reported with regard to the relationship between *CSPG2* and *HSPG2* polymorphisms and IAs susceptibility. In the Dutch population, SNPs in strong linkage disequilibrium and haplotypes constituting these SNPs in the *CSPG2* gene were associated with IAs ([@B12]), which suggested that variation in or near the *CSPG2* gene played a role in susceptibility to IAs. In another study, the polymorphisms of *HSPG2* gene were also found to be involved in the increased risk of IAs ([@B10]). Similarly, another study replicated the association of *CSPG2* and risk of IAs, and there is a trend for *HSPG2* toward association by meta-analysis ([@B14]). On the contrary, replication studies reported a lack of association of the *CSPG2* and *HSPG2* variants with IA susceptibility ([@B15], [@B16]). In addition, the different SNPs of the *CSPG2* and *HSPG2* genes also demonstrated different results, showing not all SNPs could influent the function of the proteins.

Gene *CSPG2*, ([@B17]), also known as versican (VCAN), localized on 5q12--q14, is a member of the aggrecan/versican proteoglycan family. The protein encoded is a large chondroitin sulfate proteoglycan and is a major component of the ECM. This protein is involved in cell adhesion, proliferation, migration, and angiogenesis and also plays a vital role in tissue maintenance and morphogenesis ([@B18]). *HSPG2* gene, located on chromosome 1p34.3-p36.13, encodes the perlecan protein that consists of a core protein and three long chains of glycosaminoglycans ([@B19]). The perlecan protein is a large multidomain proteoglycan that binds to and cross-links many ECM components and cell-surface molecules. Perlecan is a key component of the vascular extracellular matrix, where it helps to maintain the endothelial barrier function. It can also promote growth factor (e.g., FGF2) activity and thus stimulate endothelial growth and re-generation. Both proteins encoded by the two genes are central parts of the ECM and thereby contribute to the maintains of the vascular wall ([@B18]).

Though the present study explored the relationship between *CSPG2* and *HSPG2* polymorphisms and IAs susceptibility successfully. The present study still had some limitations that could not be ignored. First, the inconsistency of the baseline characteristics and the publication bias between the case and control groups may have distorted the meta-analysis. Second, only 4 SNPs were able to be included in the final meta-analysis, remaining much more of previous reported SNPs controversy, with regard to a large number of variants found for these two genes. In addition, the possibility of synergistic action to IAs susceptibility by haplotypes could not be ignored, however, the present meta-analysis is not able to explore it.

Conclusion
==========

The SNPs rs251124 of *CSPG2* and rs3767137 of *HSPG2* have had statistically significant associations with an increased risk of IAs susceptibility. The minor allele T of rs251124 showed a harmful effect but the minor allele A of rs3767137 demonstrated a protective role with regard to the risk of IAs. However, no such associations were found in the SNPs rs173686 of *CSPG2* and rs7556412 of *HSPG2*. Because of the increasing number of cases and controls in this analysis, the estimates of association obtained are more precise.
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